MetaCap

AbbVie (ABBV) vs Novo Nordisk A/S (NVO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AbbVie (ABBV) has outperformed Novo Nordisk A/S (NVO) over the past year, gaining 21.1% versus a loss of 20.6%. Over five years, ABBV leads with a +145.6% price change compared with -30.1% for NVO. AbbVie is the larger company by market cap ($505.89 billion vs $166.69 billion), about 3.0 times the size.

On valuation, Novo Nordisk A/S trades at a lower forward P/E (10.8x vs 17.6x for AbbVie). Novo Nordisk A/S offers the higher dividend yield (30.94% vs 2.42%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABBV+21.13%NVO-20.60%
+37%+4%-29%
Nov 21, 20251 yearNov 20, 2026
ABBV+146.21%NVO-33.57%
+163%+59%-46%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABBV versus NVO key metrics
MetricABBVNVO
Share price$286.20$37.82
Market cap$505.89B$166.69B
1-day change+0.94%-2.70%
YTD return+25.26%-25.67%
1-year return+21.13%-20.60%
5-year return+145.64%-30.07%
P/E ratio (TTM)49.189.55
Forward P/E17.6510.77
EPS (TTM)$5.82$3.96
Dividend yield2.42%30.94%
Annual dividend$6.92$11.70
Revenue (latest FY)$61.16B—
Revenue growth (YoY)+8.57%—
Net income (latest FY)$4.23B—
Gross margin70.24%—
Operating margin24.65%—
Net margin6.91%—
52-week high$302.93$64.16
52-week low$190.75$35.12
Distance from 52-week high-5.52%-41.05%
Analyst consensusbuyhold
Avg. price target upside+9.76%+20.28%
Average volume4.84M12.59M
Shares outstanding1.77B3.33B
Employees57,00068,794
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AbbVie is about 3.0 times larger than Novo Nordisk A/S by market value ($505.89B vs $166.69B).
  • ABBV has outperformed NVO by 41.7 percentage points over the past year.
  • AbbVie trades at a higher earnings multiple (49.2x vs 9.6x trailing P/E).
  • Novo Nordisk A/S offers a meaningfully higher dividend yield (30.94% vs 2.42%).

About AbbVie

ABBV stock →

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 57,000 employees

About Novo Nordisk A/S

NVO stock →

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 68,794 employees

ABBV vs NVO FAQ

Which is bigger, AbbVie or Novo Nordisk A/S?

AbbVie (ABBV) is larger, with a market capitalization of $505.89B compared with $166.69B for Novo Nordisk A/S (NVO).

Which stock has performed better over the past year, ABBV or NVO?

ABBV returned +21.13% over the past 12 months, compared with -20.60% for NVO (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, ABBV or NVO?

NVO has the lower trailing P/E at 9.6, versus 49.2 for ABBV. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, AbbVie or Novo Nordisk A/S?

Novo Nordisk A/S has the higher yield at 30.94%, compared with 2.42% for AbbVie.

Are AbbVie and Novo Nordisk A/S in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons